International Scholarly Research Notices / 2012 / Article / Tab 2

Research Article

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 2

Probability of pharmacokinetic/pharmacodynamic target (fT > MIC ≥ 35%) attainment by CVVH flow rate in acute kidney impairment subjects with residual kidney function (250 mg q12h, 4-hour infusion).

MIC (mg/L)CVVH flow rate (L/hr)
0.5123

10.9840.9810.9730.963
20.6030.5730.5140.455
40.0210.0170.0120.008
80.0000.0000.0000.000

Pharmacokinetic-pharmacodynamic target attainment probabilities for CVVH are based on a simulation of 5000 subjects using mean pharmacokinetic parameter estimates [14], with inflated between-subject variability (40% CV) and assuming a protein binding of 8.5% along with the presence of residual kidney function. Total drug CL represented a sum of 2 × CLNR, renal CL, and CVVH CL. The renal component of the clearance allowed residual kidney function with a CrCL of 30 mL/min.